Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

Table 3 Comparison of parameters between 52 weeks-remission and 52 weeks-non remission groups at 12 weeks of TCZ therapy

TCZ, tocilizumab; ROM, reactive oxygen metabolites; CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; TJC, tender joint count; SJC, swollen joint count; HAQ, health assessment questionnaire; DAS, disease activity score; CDAI, clinical disease activity index; R, remission; NR, non-remission. Values are expressed as mean ± SD. Significantly different between remission and non-remission groups, *p < 0.05, **p < 0.01

ISSN: 2520-1026